摘要
目的分析表皮生长因子受体(epidermal growth factor receptor,EGFR)阳性晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者采用参附注射液联合奥西替尼治疗的效果。方法随机选取2022年4月—2023年3月成武县人民医院收治的86例EGFR阳性晚期NSCLC患者为研究对象,按照随机数表法予以分组。对照组(43例)患者采用奥西替尼治疗,在此基础上研究组(43例)患者联用参附注射液治疗。针对两组临床疗效、外周血T淋巴细胞亚群分化簇8(cluster of differentiation,CD8^(+))、分化簇4(cluster of differentiation,CD4^(+))、CD4^(+)/CD8^(+),以及不良反应予以比较。结果与对照组有效率51.16%相比,研究组的有效率74.42%更高,差异有统计学意义(χ^(2)=4.977,P<0.05)。与对照组治疗后的指标相比,研究组CD8^(+)更低,差异有统计学意义(P<0.05),CD4^(+)、CD4^(+)/CD8^(+)更高,差异有统计学意义(P均<0.05)。与对照组结果相比,研究组白细胞减少、恶心呕吐发生率更低,差异有统计学意义(P均<0.05),两组血红蛋白减少、血小板减少、周围神经毒性发生率对比,差异无统计学意义(P>0.05)。结论EGFR阳性NSCLC患者采用参附注射液联合奥西替尼治疗效果确切,能够有效改善免疫功能,缓解治疗不良反应。
Objective To analyze the effect of Shenfu injection combined with Osimertinib in patients with epidermal growth factor receptor(EGFR)-positive advanced non-small cell lung cancer(NSCLC).Methods 86 patients with EGFR-positive advanced NSCLC admitted to Chengwu County People's Hospital were selected as the research objects and grouped according to a randomized table From April 2022 to March 2023 method.The control group(43 patients)was treated with Osimertinib,and on this basis,the study group(43 patients)was treated with Shenfu injection.The clinical efficacy,peripheral blood T lymphocyte subpopulation cluster of differentiation(CD8^(+)),cluster of differentiation(CD4^(+)),CD4^(+)/CD8^(+),and adverse reactions were compared between the two groups.Results Compared with the control group's efficiency of 51.16%,the study group achieved a higher efficiency of 74.42%,the difference was statistically significant(χ^(2)=4.977,P<0.05).Compared with the indicators after treatment in the control group,the study group had lower CD8^(+),the difference was statistically significant(P<0.05).CD4^(+)and CD4^(+)/CD8^(+)were higher,and the differences were statistically significant(both P<0.05).Compared with the results of the control group,the incidence of leukopenia and nausea and vomiting was lower in the study group,the differences were statistically significant(both P<0.05),and the results of hemoglobin reduction,thrombocytopenia,and peripheral neurotoxicity were compared between the two groups,and the results did not differ,the difference was not statistically significant(P>0.05).Conclusion The effect of EGFR-positive NSCLC patients treated with Shenfu injection combined with Osimertinib is precise,which can effectively improve the immune function and alleviate the adverse effects of treatment.
作者
陶祥波
周中民
TAO Xiangbo;ZHOU Zhongmin(Department of Oncology and Hematology,Chengwu County People's Hospital,Heze,Shandong Province,274200 China;Department of Cardiothoracic and Vascular Surgery,Chengwu County People's Hospital,Heze,Shandong Province,274200 China)
出处
《世界复合医学》
2023年第12期24-26,34,共4页
World Journal of Complex Medicine
